1. Home
  2. WENN vs ZURA Comparison

WENN vs ZURA Comparison

Compare WENN & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WENN

Wen Acquisition Corp Class A Ordinary Shares

SELL

Current Price

$10.49

Market Cap

390.2M

Sector

N/A

ML Signal

SELL

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$1.01

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WENN
ZURA
Founded
2025
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.2M
455.4M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
WENN
ZURA
Price
$10.49
$1.01
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $8.00
AVG Volume (30 Days)
342.5K
★ 6.9M
Earning Date
01-01-0001
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.09
$0.93
52 Week High
$10.49
$7.25

Technical Indicators

Market Signals
Indicator
WENN
ZURA
Relative Strength Index (RSI) 86.22 25.14
Support Level $10.41 $0.93
Resistance Level N/A $6.05
Average True Range (ATR) 0.01 0.31
MACD -0.00 -0.25
Stochastic Oscillator 80.00 2.13

Price Performance

Historical Comparison
WENN
ZURA

About WENN Wen Acquisition Corp Class A Ordinary Shares

Wen Acquisition Corp is a blank check company.

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Share on Social Networks: